Copyright: ©Author(s) 2026.
World J Orthop. Jul 18, 2026; 17(7): 121157
Published online Jul 18, 2026. doi: 10.5312/wjo.121157
Published online Jul 18, 2026. doi: 10.5312/wjo.121157
Table 1 Comparative analysis of biomechanical outcomes by groups, mean ± SD/median (interquartile range)
| Control | Celecoxib | Efficacy of celecoxib: Operated control vs operated celecoxib | Control (operated vs non-operated) | Celecoxib (operated vs non-operated) | |||
| Non-operated limb | Operated limb | Non-operated limb | Operated limb | ||||
| PEA-2 (º) | 136.7 ± 29.5 | 107.5 ± 11.6 | 122.9 ± 28.6 | 124.5 ± 28.6 | P = 0.259 | P = 0.065 | P = 0.891 |
| PEA-4 (º) | 153.4 ± 24.0 | 112.8 ± 35.2 | 145.0 ± 35.5 | 136.5 ± 29.4 | P = 0.129 | P = 0.011 | P = 0.566 |
| PEA-8 (º) | 159.1 ± 22.6 | 123.7 ± 34.0 | 167.1 ± 37.0 | 162.4 ± 34.8 | P = 0.026 | P = 0.044 | P = 0.769 |
| PEA-failure (º) | 204.6 (33.6) | 138.1 (33.4) | 229.4 (17) | 222.5 (24.6) | P = 0.015 | P = 0.043 | P = 0.247 |
| Failure torque (N·cm) | 18.4 ± 8.9 | 21.2 ± 8.9) | 32.3 ± 9.9 | 38.8 ± 11.1 | P = 0.002 | P = 0.588 | P = 0.187 |
| Elastic torque (N·cm) | 13.1 ± 8.9 | 19.8 ± 8.9 | 29.1 ± 11.7 | 34.7 ± 11.6 | P = 0.009 | P = 0.063 | P = 0.294 |
| Stiffness (N·cm/º) | 0.3 (0.4) | 0.5 (0.4) | 0.6 (0.4) | 0.8 (0.8) | P = 0.637 | P = 0.293 | P = 0.579 |
| Energy (N·cm·º) | 1.1 (1.4) | 0.9 (2.4) | 2.2 (1.8) | 3.7 (2.2) | P = 0.050 | P = 0.463 | P = 0.089 |
Table 2 Comparative analysis of histological outcomes by groups, median (interquartile range)
| Control | Celecoxib | Efficacy of celecoxib: Operated control vs operated celecoxib | Control (operated vs non-operated) | Celecoxib (operated vs non-operated) | ||||
| Non-operated limb | Operated limb | Non-operated limb | Operated limb | |||||
| Quantitative evaluation | ||||||||
| Capsule area (mm2) | C | 1.65 (0.75) | 2.90 (2.47) | 1.98 (1.86) | 2.98 (2.60) | P = 0.805 | P = 0.007 | P = 0.128 |
| L | 1.76 (1.64) | 2.21 (1.42) | 2.21 (0.60) | 2.30 (1.10) | P = 0.710 | P = 0.097 | P = 0.805 | |
| Capsule thickness (mm) | C | 0.53 (0.33) | 0.84 (0.53) | 0.55 (0.61) | 1.22 (0.714) | P = 0.209 | P = 0.007 | P = 0.011 |
| L | 0.43 (0.29) | 0.68 (0.75) | 0.68 (0.40) | 0.51 (0.32) | P = 0.535 | P = 0.073 | P = 0.710 | |
| Semi-quantitative evaluation | ||||||||
| Amount of fibrosis | C | 0.5 (1.25) | 2 (1) | P = 0.003 | ||||
| L | 1 (2) | 1 (1) | P = 0.638 | |||||
| Fibrosis density | C | 1.5 (1) | 1 (1) | P = 0.606 | ||||
| L | 2 (1) | 2 (1) | P = 1.00 | |||||
| Cellular density | C | 1 (0.25) | 2 (2) | P = 0.027 | ||||
| L | 1 (0) | 2 (1) | P = 0.275 | |||||
| Cellular organization (disorganized) | C | 6 (100%) | 4 (57.1%) | P = 0.192 | ||||
| L | 6 (85.7%) | 5 (83.3%) | P = 1.00 | |||||
| Cellular morphology | C | 1 (0.25) | 1 (1) | P = 0.327 | ||||
| L | 1 (0) | 1 (0) | P = 0.593 | |||||
| Number of blood vessels | C | 1 (0.5) | 2 (1) | P = 0.030 | ||||
| L | 1 (1) | 1 (0) | P = 0.389 | |||||
- Citation: Palacios-Díaz L, Diez Sánchez B, González-García Á, Pena-Burgos EM, Pozo-Kreilinger JJ, Carrascal-Morillo MT, Bustos A, Sanchez-Urgelles P, Antuña S, Barco R. Early oral celecoxib prevents contracture and modulates capsular fibrosis in a validated model of post-traumatic arthrofibrosis. World J Orthop 2026; 17(7): 121157
- URL: https://www.wjgnet.com/2218-5836/full/v17/i7/121157.htm
- DOI: https://dx.doi.org/10.5312/wjo.121157